Skip to main content
main-content

01.12.2014 | Case Report | Ausgabe 1/2014 Open Access

Clinical Sarcoma Research 1/2014

Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature

Zeitschrift:
Clinical Sarcoma Research > Ausgabe 1/2014
Autoren:
Mashaal Dhir, David G Crockett, Todd M Stevens, Peter T Silberstein, William J Hunter, Jason M Foster
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​2045-3329-4-8) contains supplementary material, which is available to authorized users.

Competing interest

The authors declare that they have no competing interest.

Authors’ contributions

MD – Conception and design, analysis and interpretation of the data, drafting and critical review of manuscript, final approval of the manuscript. DGC – conception, data acquisition, and final approval of manuscript. TMS & WJH - conception, data acquisition, critical review and final approval of manuscript. PTS - data acquisition, critical review and final approval of manuscript. JMF - Conception and design, analysis and interpretation of the data, drafting and critical review of manuscript, final approval of the manuscript.

Abstract

Dermatofibrosarcoma Protuberans (DFSP) is a rare skin tumor, characterized by frequent local recurrence but is seldom metastatic. It is histologically characterized by storiform arrangement of spindle cells. Cytogenetically, most tumors are characterized by translocation 17:22 leading to overexpression of tyrosine kinase PDGFB which can be targeted with tyrosine kinase inhibitor, Imatinib. We describe the first case of unresectable pancreatic metastases from DFSP treated with neoadjuvant Imatinib and subsequently R0 metastectomy. Additionally, a comprehensive systematic review of DFSP pancreatic metastases and the current published data on the use of Imatinib in DFSP is summarized.
Zusatzmaterial
Additional file 1: Summary of studies of pancreatic metastases in patients with Dermatofibrosarcoma Protuberans. (XLSX 12 KB)
13569_2014_68_MOESM1_ESM.xlsx
Additional file 2: Summary of case reports utilizing Imatinib for the treatment of patients with Dermatofibrosarcoma Protuberans. (XLSX 16 KB)
13569_2014_68_MOESM2_ESM.xlsx
Additional file 3: Summary of case series utilizing Imatinib for the treatment of patients with Dermatofibrosarcoma Protuberans. (XLSX 15 KB)
13569_2014_68_MOESM3_ESM.xlsx
Additional file 4: Summary of phase II studies utilizing Imatinib for the treatment of patients with Dermatofibrosarcoma Protuberans. (XLSX 11 KB)
13569_2014_68_MOESM4_ESM.xlsx
Additional file 5: Summary of the case reports and series utilizing Imatinib for the treatment of pediatric patients with Dermatofibrosarcoma Protuberans. (XLSX 11 KB)
13569_2014_68_MOESM5_ESM.xlsx
Authors’ original file for figure 1
13569_2014_68_MOESM6_ESM.tiff
Authors’ original file for figure 2
13569_2014_68_MOESM7_ESM.pdf
Authors’ original file for figure 3
13569_2014_68_MOESM8_ESM.pdf
Authors’ original file for figure 4
13569_2014_68_MOESM9_ESM.tiff
Authors’ original file for figure 5
13569_2014_68_MOESM10_ESM.tiff
Authors’ original file for figure 6
13569_2014_68_MOESM11_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Clinical Sarcoma Research 1/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise